Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EPS (Weighted Average and Diluted) (2016 - 2025)

BioCorRx (BICX) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with -$0.26 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 225.0% to -$0.26 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.35 through Dec 2025, changed 0.0% year-over-year, with the annual reading at -$0.19 for FY2025, 61.22% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.26 in Q4 2025 for BioCorRx, down from $0.06 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q3 2025 to a low of -$0.26 in Q4 2025.